Recce Scouts New Synthetic Anti-Infectives to Overcome Resistance

It’s World Antimicrobial Awareness Week 2021 and we are shining a light on Australia’s expertise and innovations to fight superbugs. In this episode we catch up with Recce Pharmaceuticals, a company out of Western Australia that is pioneering the development and commercialisation of a new class of synthetic anti-infectives designed to overcome resistance. Its lead compound is the only synthetic polymer and sepsis drug candidate in development, as listed in the Pew Charitable Trusts Global New Antibiotics in Development Pipeline and has been awarded the US regulator’s Fast Track Designation under the GAIN Act.Recce Pharmaceuticals’ Chief Executive Officer James Graham, joins the podcast from the United States after attending the World Antimicrobial Resistance Congress in Washington DC.Joining host Caroline Duell is Andrew Bowskill, MTPConnect’s Director of Stakeholder Engagement for Queensland and the co-chair of AAMRNet, Australia’s first industry led, multi-stakeholder Antimicrobial Resistance Network, established and operated by MTPConnect.